Tag: dementia prevention

Prince Mario-Max Schaumburg-Lippe: World Report: Alzheimer’s No Longer Untreatable

For decades, families heard the same sentence when Alzheimer’s disease entered the room: there is nothing to be done but manage the decline. This year’s World Alzheimer Report says that sentence is no longer true. Published by Alzheimer’s Disease International to mark World Alzheimer’s Day, the 2026 report argues that after years of slow progress, clinical trials are on the brink of diagnostic and medical breakthroughs, and that the disease is “no longer universally described as untreatable.” It is one of the most hopeful documents the dementia field has produced in a generation.

The turning point

The shift is real, and it has a name: donanemab and lecanemab. These are the first fully approved treatments shown to modestly slow early Alzheimer’s decline rather than merely easing symptoms. They work by targeting and clearing the amyloid plaque that builds up in the brains of people with Alzheimer’s years before symptoms appear. Both have now been approved in multiple countries; in Australia, regulators approved donanemab in May 2025 for mild cognitive impairment due to Alzheimer’s, with lecanemab following in September 2025.

“Modestly” is doing honest work in that sentence, and the report does not oversell it. A cure remains far away. But Cath Mummery, director of the UK’s Dementia Trials Network, described the new drugs in the report as “the first brick,” and bricks are how walls get built. The pipeline behind them is the real story: 158 potential therapies are now being tested across 192 clinical trials worldwide, a rise of roughly 40 percent over the past decade. Eight Phase III trials are expected to report results during 2026. About three-quarters of the medicines in development are designed to modify the underlying disease process, not just mask symptoms.

Prevention is moving to the center

Perhaps the most consequential finding is not about drugs at all. The report highlights growing evidence that a large share of dementia cases could be delayed or prevented by addressing modifiable risk factors, as many as 14 of them, including high blood pressure, depression, physical inactivity, smoking, diabetes, alcohol use, and high cholesterol. Researchers increasingly treat Alzheimer’s the way cardiology treated heart disease a generation ago: as a condition you can see coming and work against.

Dr. Campbell Le Heron, a neurologist and Alzheimers NZ spokesperson, put it plainly: for a long time there has been what he called a fairly nihilistic view in the dementia world, the idea that cognitive decline just happens with age and nothing can be done. “These trials are showing us that we can potentially do something about it, at least in certain situations,” he said. “Our biological understanding of the condition is identifying ways we can actually prevent it.”

The hard part: finding volunteers

The report is also candid about the bottleneck. Trials need people, and dementia trials are picky: specific disease stages, proof of Alzheimer’s-related proteins, the absence of certain other conditions, a study partner. About 55,000 participants are needed, and because so many volunteers fail screening, researchers estimate that as many as 350,000 people may need to step forward. The report’s conclusion on this point is worth quoting: taking part in dementia research should depend on “realistic opportunity for everyone who wishes to consider it,” not on persistence or good fortune.

This is where families come in. Practical steps exist right now. Anyone can search ClinicalTrials.gov by condition and location, or use the Alzheimer’s Association’s TrialMatch service, to find studies nearby. Healthy volunteers are wanted too, not just people with symptoms. And the everyday prevention advice keeps getting stronger: control blood pressure, stay active, protect your hearing, stay socially connected, treat depression. It echoes the research into brain blood flow in Alzheimer’s risk groups that is quietly building the case for early action, and it sits alongside the encouraging long-term data for lupus treatment as evidence that chronic disease medicine is having a genuinely good year.

What changes now

Numbers give the report its weight. More than 55 million people were living with dementia worldwide as of 2019, and the figure is projected to pass 139 million by 2050 as populations age. Dementia is becoming one of the leading causes of death on the planet. Against that backdrop, the report’s central claim, that we stand “on the cusp of a giant leap forward at the intersection of innovation in diagnostics, treatments, and risk reduction,” reads less like hype and more like arithmetic. The investment is there. The pipeline is there. The volunteers are the missing piece.

Chris Lynch, the acting CEO of Alzheimer’s Disease International, wrote in the report: “Never before has there been so much focus, investment, and hope in dementia research.” Hope is not a treatment. But for the families who have been told for years that nothing could be done, a major global report saying otherwise, with 158 therapies in trials to back it up, is the beginning of a different conversation. The next decade of dementia care will be built by the people who show up for it, in clinics and in trials. That is something all of us can be part of.

Prince Mario-Max Schaumburg-Lippe: Rapamycin Boosts Brain Blood Flow in Alzheimer’s Risk Group

For the 25 million or so people worldwide who carry the APOE4 gene variant, the statistics have always felt like a sentence handed down early. Carry one copy of the variant and your lifetime risk of Alzheimer’s climbs roughly threefold; carry two and it climbs much higher. Yet the disease itself may not show up for decades. A new study out this week suggests that window, the long quiet stretch between risk and illness, might be exactly where medicine should aim.

Researchers at the University of Missouri gave a small group of healthy middle-aged adults a low daily dose of rapamycin, a drug long used to prevent organ transplant rejection, for four weeks. The twist: only the nine participants who carried APOE4 showed the benefit. Their cerebral blood flow rose by more than 15 percent across multiple brain regions. The fourteen non-carriers saw no significant change.

What the trial actually measured

Ai-Ling Lin, a professor in the School of Medicine and an investigator at the university’s Roy Blunt NextGen Precision Health building, designed the study around a simple observation. People with APOE4 tend to show reduced blood flow in certain brain regions years, sometimes decades, before memory problems appear. Dimmed circulation has long been treated as an early warning sign. Lin’s question was whether it could also be an early treatment target.

The participants, all between 45 and 65 and cognitively normal, took one milligram of rapamycin daily. Along with the blood-flow gains, the APOE4 group showed calmer inflammatory markers and healthier metabolic profiles, with minimal side effects. The paper, published in the Journal of Cerebral Blood Flow & Metabolism, frames the result as a proof of precision medicine: the right drug, for the right biology, at the right time.

Why blood flow matters more than we thought

Alzheimer’s research spent years fixated on amyloid plaques, the sticky protein clumps found in patients’ brains. Billions went into clearing them, with underwhelming results. Blood flow was the boring cousin of the field, harder to measure, less dramatic to describe.

That is changing. The brain burns roughly a fifth of the body’s energy despite weighing about three pounds, and it has no meaningful fuel reserve. When its plumbing underperforms, neurons starve in slow motion. Lin’s earlier mouse studies showed rapamycin could slow brain aging and restore circulation in APOE4 mice; the human data now rhymes with it. Improved flow means better waste clearance, better nutrient delivery, and a blood-brain barrier under less strain.

Rapamycin itself is no newcomer. Discovered in soil bacteria on Easter Island, it has been prescribed for decades. Repurposing an approved drug with a known safety profile is far faster than building a new molecule from scratch, which is part of why geroscientists have watched this class of compounds so closely. Lin’s group is already thinking about the next questions: how long the blood-flow gains persist after the four weeks end, whether the effect scales with dose, and, eventually, whether better plumbing actually translates into sharper memory years down the line. Those are the right questions, asked in the right order.

A stroll through one of the city’s many lively street fairs won’t replace medicine, but staying socially and physically active is exactly the kind of low-tech brain support the science keeps endorsing.

What comes next

Let’s keep the excitement honest. Twenty-three people is a pilot study, not a prescription. Four weeks is a blink. The trial measured blood flow and biomarkers, not memory scores or dementia rates, and those outcomes will need years of follow-up in much larger groups. Nobody should ask their doctor for rapamycin off-label on the strength of one paper, and Lin herself frames the work as a starting point, not a finish line.

Still, the direction is genuinely new. Instead of waiting for damage and trying to reverse it, the field is learning to spot the earliest wobble in the system and steady it. Genotype-specific responses, drugs matched to a person’s biology rather than their diagnosis, represent the kind of medicine Alzheimer’s prevention has been missing. And there is something quietly hopeful about the timing: the intervention worked best in healthy people who had no symptoms at all. Prevention, it turns out, may begin long before anyone thinks they are sick.

Small steps, taken early, have a way of adding up. A brisk morning walk, a real breakfast instead of a skipped one (the city’s breakfast sandwich game is stronger than ever), a conversation that keeps your mind turning, all of it feeds the same three-pound engine this study is trying to protect. Medicine may soon have one more tool for the job. The rest of the work is ours.